If a peptide finishes appropriate professional tests or if Congress changes intensifying regulations, some substances can return to compounding eligibility. However there’s no timeline, and it would need considerable initiative and financial investment to make it happen. Price should consist of pharmaceutical-grade sourcing and clinical oversight– not simply the peptide. If a supplier costs considerably
